Total | HER2-positive | HER2-negative | p-value | |
---|---|---|---|---|
Age, years | ||||
Median (min; max) | 75.5 (51.0; 87.0) | 67.0 (54.0; 86.0) | 82.0 (51.0; 87.0) | 0.46a |
Q1; Q3 | 55.5; 84.25 | 55.0; 79.5 | 61.5; 84.5 | |
pT, n (%) | ||||
pT1 | 5 (35.7) | 2 (14.3) | 3 (21.4) | 1.00a |
pT2 | 7 (50.0) | 2 (14.3) | 5 (35.7) | |
pT3 | 1 (7.1) | 1 (7.1) | 0 | |
pT4 | 1 (7.1) | 0 | 1 (7.1) | |
Tumor size, mm | ||||
Median (min; max) | 22.5 (10.0; 70.0) | 23.0 (14.0; 70.0) | 22.0 (10.0; 31.0) | 0.35a |
Q1; Q3 | 17.0; 30.3 | 18.0; 52.5 | 15.5; 28.5 | |
Tumor type, n (%) | ||||
NST | 11 (78.6) | 5 (35.7) | 6 (41.9) | 0.15b |
ILC | 3 (21.4) | 0 | 3 (21.4) | |
pN, n (%) | ||||
0 | 8 (57.1) | 3 (21.4) | 5 (35.7) | 0.87b |
1 | 6 (42.9) | 2 (14.3) | 4 (28.6) | |
Systemic therapy, n (%) | ||||
Response | 11 (78.6) | 4 (28.6) | 7 (50) | 0.92b |
Non-response | 3 (21.4) | 1 (7.1) | 2 (14.3) | |
Follow-up status, n (%) | ||||
Relapse | 2 (14.3) | 0 | 2 (14.3) | 0.23b |
Death | 2 (14.3) | 1 (7.1) | 1 (7.1) | |
HER2 status (IHC), n (%) | ||||
1+ | 7 (50.0) | 0 | 7 (50.0) | <0.01b |
2+ | 3 (21.4) | 1 (7.1) | 2 (14.3) | |
3+ | 4 (28.6) | 4 (28.6) | 0 | |
HER2 status (SRc), n (%) | ||||
Positive | 5 (35.7) | 5 (35.7) | 0 | <0.001b |
Negative | 9 (64.3) | 0 | 9 (64.3) |